



## Cynvec to Present at New York Biotechnology Association 18<sup>th</sup> Annual Meeting

**New York, NY, April 13, 2009** – Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will present at the NYBA 18<sup>th</sup> Annual Meeting, Bioscience Industry Showcase on Monday, April 20, 2009 at 9:40am. The presentation will be held at the Marriott Marquis Hotel, Belasco Room, in New York City.

### **About Cynvec LLC**

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in ovarian cancer in the third quarter of 2009. The sindbis vector has also demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor, which is implicated in Alzheimer's disease, multiple sclerosis and Parkinson's. Further information on Cynvec can be found at [www.cynvec.com](http://www.cynvec.com).

### Contacts:

Chris Smith (media)  
SmithSolve  
973-442-1555  
[chris.smith@smithsolve.com](mailto:chris.smith@smithsolve.com)

Rhonda Chiger (investors)  
Rx Communications Group  
917-322-2569  
[rchiger@rxir.com](mailto:rchiger@rxir.com)